Ovarian Adenocarcinoma — Trials

Ovarian Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

183 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 83
Recruiting: 38
Ph III recruiting: 5
Growth YoY: —
Industry share: 24%
Top sponsor: National Cancer Institute (NCI)
Termination share: 44.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (25)

clinicaltrialsPublishedShowing 51–54 of 54 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00814086	Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer	completed	Phase 1	23	Gynecologic Oncology GroupNETWORK	1	Dec 31, 2014	clinicaltrials
NCT01294293	TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer	completed	Phase 1	20	Gynecologic Oncology GroupNETWORK